Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kentaro Takeda

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 21, 2022
[Introduction of Oncology Dose-Finding Trial Designs]Kentaro Takeda
Therapeutic Innovation & Regulatory Science|September 18, 2018
Incorporating Historical Data in Bayesian Phase I Trial Design: The Caucasian-to-Asian Toxicity Tolerability ProblemKentaro Takeda, Satoshi Morita
Journal of Biopharmaceutical Statistics|December 22, 2025
Multi-armed bandits backfill Bayesian optimal interval designMasahiro Kojima, Kentaro Takeda
Pharmaceutical Statistics|January 27, 2018
Bayesian dose-finding phase I trial design incorporating historical data from a preceding trialKentaro Takeda, Satoshi Morita
Statistics in Medicine|October 26, 2021
Constrained hierarchical Bayesian model for latent subgroups in basket trials with two classifiersKentaro Takeda, Shufang Liu, Alan Rong
Pharmaceutical Statistics|December 14, 2022
Incorporating historical information to improve dose optimization design with toxicity and efficacy endpoints: iBOIN-ETYunqi Zhao, Rachael Liu, Kentaro Takeda
Therapeutic Innovation & Regulatory Science|April 22, 2023
Comparison Between Simultaneous and Sequential Utilization of Safety and Efficacy for Optimal Dose Determination in Bayesian Model-Assisted DesignsRan Li, Kentaro Takeda, Alan Rong
Pharmaceutical Statistics|April 28, 2018
BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomesKentaro Takeda, Masataka Taguri, Satoshi Morita
Pharmaceutical Statistics|March 29, 2026
A Constrained Hierarchical Bayesian Model Considering Latent Biomarker Subgroups for Time-To-Event Endpoints in Randomized Phase II TrialsYifei Huang, Kentaro Takeda, Yongyun Zhao
Statistics in Medicine|May 19, 2025
COMIC: A Bayesian Dose Optimization Design for Drug Combination in Multiple Indications With Application to CAR-T TherapiesKai Chen, Kentaro Takeda, Ying Yuan
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 21, 2022
[Introduction of Oncology Dose-Finding Trial Designs]Kentaro Takeda
Therapeutic Innovation & Regulatory Science|September 18, 2018
Incorporating Historical Data in Bayesian Phase I Trial Design: The Caucasian-to-Asian Toxicity Tolerability ProblemKentaro Takeda, Satoshi Morita
Journal of Biopharmaceutical Statistics|December 22, 2025
Multi-armed bandits backfill Bayesian optimal interval designMasahiro Kojima, Kentaro Takeda
Pharmaceutical Statistics|January 27, 2018
Bayesian dose-finding phase I trial design incorporating historical data from a preceding trialKentaro Takeda, Satoshi Morita
Statistics in Medicine|October 26, 2021
Constrained hierarchical Bayesian model for latent subgroups in basket trials with two classifiersKentaro Takeda, Shufang Liu, Alan Rong
Pharmaceutical Statistics|December 14, 2022
Incorporating historical information to improve dose optimization design with toxicity and efficacy endpoints: iBOIN-ETYunqi Zhao, Rachael Liu, Kentaro Takeda
Therapeutic Innovation & Regulatory Science|April 22, 2023
Comparison Between Simultaneous and Sequential Utilization of Safety and Efficacy for Optimal Dose Determination in Bayesian Model-Assisted DesignsRan Li, Kentaro Takeda, Alan Rong
Pharmaceutical Statistics|April 28, 2018
BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomesKentaro Takeda, Masataka Taguri, Satoshi Morita
Pharmaceutical Statistics|March 29, 2026
A Constrained Hierarchical Bayesian Model Considering Latent Biomarker Subgroups for Time-To-Event Endpoints in Randomized Phase II TrialsYifei Huang, Kentaro Takeda, Yongyun Zhao
Statistics in Medicine|May 19, 2025
COMIC: A Bayesian Dose Optimization Design for Drug Combination in Multiple Indications With Application to CAR-T TherapiesKai Chen, Kentaro Takeda, Ying Yuan
Pageof 7